Comparative Pharmacology
Head-to-head clinical analysis: AQUASOL A versus VITAMIN A PALMITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUASOL A versus VITAMIN A PALMITATE.
AQUASOL A vs VITAMIN A PALMITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin A is essential for vision, epithelial differentiation, bone growth, reproduction, and immune function. It acts as a retinol-binding protein that regulates gene expression through retinoic acid receptors.
Vitamin A palmitate is a retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and vision. It is converted to retinol and then to retinaldehyde and retinoic acid, essential for phototransduction, epithelial integrity, and immune function.
100,000 to 200,000 IU intramuscularly once monthly for prophylaxis; 50,000 to 100,000 IU intramuscularly daily for 3 days for severe deficiency.
Adult: 1,500-3,000 IU (450-900 mcg RAE) orally once daily for vitamin A deficiency; IM administration not recommended due to local toxicity.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 h); prolonged in renal impairment; clinical context: steady-state achieved in ~5-7 days with daily dosing.
Terminal elimination half-life is approximately 7–14 days for retinol in the liver; clinical effects persist for weeks due to extensive hepatic storage.
Renal: ~60% as metabolites; fecal: ~30% as unchanged drug and metabolites; biliary: ~10%.
Primarily hepatobiliary; >90% of retinol esters and metabolites excreted in feces via bile; less than 10% renally eliminated as water-soluble metabolites (e.g., retinoic acid glucuronides).
Category C
Category C
Vitamin A
Vitamin A